Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL.
Lin CC, et al. Among authors: xu l.
Res Sq [Preprint]. 2023 Jul 10:rs.3.rs-2966905. doi: 10.21203/rs.3.rs-2966905/v1.
Res Sq. 2023.
PMID: 37502925
Free PMC article.
Updated.
Preprint.